

## Guideline Development Group

## Guidelines on doxycycline prophylaxis for the prevention of sexually transmitted infections

Biographies of proposed Guideline Development Group members [27 May 2025]

**Disclaimer:** In order to enhance its management of conflicts of interest as well as strengthen public trust and transparency in connection with WHO meetings and activities involving the provision of technical/normative advice, the names and brief biographies of individuals ("Published Information") being considered for participation in a WHO-convened Guideline Development Group are disclosed for public notice and comment.

The Published Information is provided by the experts themselves and is the sole responsibility of the individuals concerned. WHO is not responsible for the accuracy, veracity and completeness of the Published Information provided. Furthermore, in no event will WHO be responsible or liable for damages in relation to the use of, and reliance upon, the Published Information.

The comments received by WHO through the public notice and comment process are treated confidentially and their receipt will be acknowledged through a generic email notification to the sender. Comments brought to the attention of WHO through this process are an integral component of WHO's conflict of interest assessment process and are carefully reviewed. WHO reserves the right to discuss information received through this process with the relevant expert and disclose to this expert the name and affiliation of the provider of such information. Upon review and assessment of the information received through this process, WHO, in its sole discretion, may take appropriate management action in accordance with its policies.

Guideline Development Groups provide technical and/or normative advice and recommendations to WHO. Participation in a Guideline Development Group convened by WHO does not necessarily mean that the views expressed by the expert concerned are shared by WHO and/or represent the decisions or stated policy of WHO. The list of participating experts, a summary of relevant interests disclosed by such experts, and any appropriate mitigation measures taken by WHO relating to the management of conflicts of interests, will be reported publicly in accordance with WHO policies.

**Dr Amina El Kettani** is a public health and field epidemiology graduate from the National School of Public Health, Rabat-Morocco. She is a medical officer at the National AIDS, STIs, and Hepatitis program, Ministry of Health, Morocco, overseeing the national STIs control program since 2006. She has coordinated several national STI surveys and reviews of the national STI syndromic approach. Dr El Kettani has been a member of the WHO STIs Guideline Development Group.

Professor Andrew Mujugira is a Senior Research Scientist at Makerere University Infectious Diseases Institute and Affiliate Assistant Professor at the University of Washington. With 21 years of experience in HIV prevention trials in East and Southern Africa, his research has influenced global and national HIV/STI policies. He leads several PrEP effectiveness trials and studies on combination HIV/STI prevention tools for underserved populations in Uganda.

Professor Catriona S. Bradshaw is Head of Research Translation and Mentorship at Melbourne Sexual Health Centre, Monash University, and Alfred Hospital. She is a Clinical Professor at the University of Melbourne and Principal Research Fellow at The Burnet Institute. Her research focuses on improving STI treatment and control. An NHMRC Leadership Fellow and technical advisor to WHO, she has received the L'Oréal-UNESCO Women in Science Award (2009) and the Eureka Prize for Infectious Diseases (2022).

**Danvic Rosadiño** is Head of Program and Innovations at LoveYourself Inc., a Manila-based organization promoting self-worth among LGBTQ+ and youth. He holds a Diploma in International Health from the University of the Philippines and was a Surveillance Assistant at the Department of Health. Danvic has led HIV PrEP workshops across Asia and served on WHO Clinical Guideline Development groups.

**Dr Jan Derek Junio** is a physician specializing in community medicine and health program management. He spearheaded clinical guidelines at the Disease Prevention and Control Bureau, Department of Health (DOH), Philippines. Currently, he is the DOH HIV Program Manager, leading national HIV/AIDS and STI initiatives. He previously served as a Municipal Health Officer and holds degrees in Medicine and Business Administration from the University of the Philippines.

**Professor Jeffrey D. Klausner** is a board-certified internist and infectious disease specialist. He served as CDC EIS Officer, Deputy Health Officer in San Francisco, and Branch Chief for HIV/TB at CDC in South Africa. At UCLA, he led NIH-funded studies on STIs and HIV prevention. Since 2021, he is Clinical Professor of Population and Public Health Services at USC, focusing on optimizing STI and HIV prevention, treatment, and care.

**Dr Jorge A. Gallardo-Cartagena** is a Peruvian physician-scientist specializing in HIV and STI prevention in Latin America. He leads PrEP PERU, a project assessing PrEP adherence among MSM in Lima. Awarded the 2022 UW/Fred Hutch CFAR Mentored International Investigator Award, he studied bacterial STIs and doxycycline use. As Protocol Co-Chair of HPTN 113, he evaluates mHealth tools for PrEP uptake among Latino MSM. He is based at CITBM - UNIDEC in Lima.

**Professor Laith J. Abu-Raddad** is a Professor of Population Health Sciences at Weill Cornell Medicine-Qatar. His research on the epidemiology of infectious diseases, especially STIs, HIV, hepatitis C, and COVID-19, across the world and in the Eastern Mediterranean region. His work has influenced public health policies globally, and he has advised international organizations.

**Luca Stevenson** is a seasoned advocate with over 20 years of experience in sex workers' rights, LGBTQI advocacy, and sexual health. He has led major organizations including ESWA and ICRSE, and currently serves as Global Lead for Community Engagement at IPPF. Luca also heads the Jasmine Project at Médecins du Monde and sits on several international boards. His work focuses on empowering marginalized communities through strategic partnerships, advocacy, and inclusive policy development.

**Professor Magnus Unemo** is an Associate Professor at Örebro University, Sweden, and Honorary Professor at University College London. He directs the WHO Collaborating Centre for Gonorrhoea and Other STIs and the Swedish Reference Laboratory for STIs. He leads the Euro-GASP for ECDC and WHO GASP/EGASP. His research focuses on *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, *Mycoplasma genitalium*, *Trichomonas vaginalis*, and syphilis. He has contributed to numerous PubMed-indexed publications and WHO guidelines.

Professor Marc Mendelson is Professor and Head of Infectious Diseases at Groote Schuur Hospital, University of Cape Town. He co-founded the South African Antibiotic Stewardship Programme and chaired the South African Ministerial Advisory Committee on AMR (2014-2022). He advises the WHO, World Economic Forum, G20, and other global bodies on AMR. He has led the Federation of Infectious Diseases Societies of Southern Africa and the International Society for Infectious Diseases.

**Dr Mayara Secco Torres da Silva** graduated from Federal Fluminense University and Queen Mary, University of London. She completed her residency at INI-Fiocruz, where she also earned her master's and PhD. She is an infectious disease physician, faculty member, and researcher focusing on HIV and STI prevention, implementation science, sexual and gender minorities, and community engagement. She has experience in multicenter studies on HIV PrEP, mpox, and STI prevention in Latin America.

**Dr Nadia Badran** has over 30 years of experience in health, social promotion, education, and counselling for all age groups. She has led numerous workshops in Lebanon and the MENA region on health, mental health, HIV/STIs, and inclusivity. Dr Badran develops programs on SRH, mental health, gender identity, substance use, and HIV/AIDS. She advocates for vulnerable groups, collaborates with UN agencies and NGOs, and is a WHO regional expert team member.

**Dr Nazila Ganatra** has over 20 years of experience in Kenya's Public Health Sector. She is the programme manager for viral hepatitis and STIs at NASCOP, Ministry of Health, Kenya. She oversees strategy development, implementation, capacity building, and research for evidence-based policies. Dr Ganatra has led various national health programs, chaired TB/HIV and Malaria committees, and is a member of the COVID-19 vaccine deployment task force.

**Dr Pham Thi Lan** specializes in dermatology and venereology at Hanoi Medical University, Vietnam, and holds a PhD from Karolinska Institute, Sweden. She is a clinical specialist and senior lecturer at the National Hospital of Dermatology and Venereology in Hanoi. Dr Lan coordinates the WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) in Vietnam and has worked on antibiotic resistance projects, providing technical assistance and contributing to Vietnam's national STI guidelines.

**Rena Janamnuaysook** is a Program Manager at the Institute of HIV Research and Innovation (IHRI) in Bangkok, Thailand. She co-established Tangerine Clinic, the first transgender-led clinic in the region. Rena manages HIV research and programs for key populations in Thailand and Asia, focusing on same-day antiretroviral treatment, viral hepatitis C, and transgender health. She co-founded the Thai Transgender Alliance and contributes to WHO guidelines on HIV prevention and transgender health.

**Dr Vita Jongen** is an infectious disease epidemiologist specializing in STI and HIV prevention. She holds an MSc from Utrecht University and a PhD from the Public Health Service of Amsterdam. She works at the Public Health Service of Amsterdam and Dutch HIV Monitoring. Her recent work includes innovations in STI and HIV prevention, such as informal doxyPEP use and digital vending machines for STI testing.

**Dr Yogi Prasetia** a medical doctor from Udayana University, founded Bali Medika Clinic, focusing on LGBTQ+ sexual health. The clinic offers same-day HIV testing and treatment, PCR CT/NG, multiplex STI testing, and HIV RNA tests. Serving over 900 patients monthly, the clinic provides PrEP, PEP, and doxyPEP for MSM. Dr Prasetia's passion for sexual health and STIs drives continuous upgrades in testing protocols and services.

**Professor Yonatan Grad** is a Professor of Immunology and Infectious Diseases at Harvard Chan School of Public Health. He earned his M.D. and Ph.D. from Harvard Medical School, trained at Brigham and Women's Hospital and Massachusetts General Hospital, and completed postdoctoral work at Harvard Chan School. His research focuses on preparing for and responding to infectious disease threats, particularly *Neisseria gonorrhoeae*, by understanding microbial evolution and human ecology.